KAIST medical scientists and their colleagues confirmed that the type I interferon response plays a pivotal role in exacerbating inflammation in severe COVID-19 cases. Severe COVID-19 has been shown to be caused by a hyper-inflammatory response. Particularly, inflammatory cytokines secreted by classical monocytes and macrophages are believed to play a crucial role in the severe progression of COVID-19.
A new single-cell RNA sequencing analysis of more than 59,000 cells from three different patient cohorts provided a detailed look at patients’ immune responses in severe cases of COVID-19. The results suggest that patients with severe cases of COVID-19 experience increased regulation of the type I interferon (IFN-I) inflammation-triggering pathway, a signature that the researchers also observed in patients hospitalized with severe cases of influenza.
Their findings suggest that anti-inflammatory treatment strategies for COVID-19 should also be aimed toward the IFN-I signaling pathway, in addition to targeting inflammatory molecules such as TNF, IL-1, and IL-6, which have been associated with COVID-19.
The research team under Professor Eui-Cheol Shin from the Graduate School of Medical Science and Engineering sequenced the RNA from a total of 59,572 blood cells obtained from four healthy donors, eight patients with mild or severe COVID-19, and five patients with severe influenza.
By comparison, patients with severe cases of influenza showed increased expression of various IFN-stimulated genes, but did not experience TNF/IL-1 responses as seen in COVID-19 patients. Unlike the flu cohort, patients in the severe COVID-19 cohort exhibited the IFN-I signature concurrently with TNF/IL-1-driven inflammation – a combination also not seen in patients with milder cases of COVID-19.
Their result, along with past mouse studies that highlight how the timing of IFN-I expression is critical to determining the outcome of SARS, support targeting IFN-I as a potential treatment strategy for severe COVID-19.
Professor Shin said, “This research provides insights for designing therapeutic options for COVID-19 by investigating very closely how the immune cells of COVDI-19 patients develop. We will continue to conduct research on novel therapeutic immune mechanisms and target therapeutic anti-inflammatory medication to improve the survival of severe COVID-19 patients.”
This study, conducted in collaboration with Severance Hospital at Yonsei University, Asan Medical Center, and Chungbuk National University, was featured in Science Immunology on July 10. This work was funded by Samsung Science and Technology Foundation and SUHF Fellowship.
< Figure: Analysis of blood immune cells at a single-cell level has revealed a cytokine signature associated with the development of severe COVID-19. >
Science Immunology 10 Jul 2020:
Vol. 5, Issue 49, eabd1554
Graduate School of Medical Science and Engineering
Laboratory of Immunology & Infectious Diseases (http://liid.kaist.ac.kr/)
COVID-19 Task Force responds 24-7 and ISSS provides returning international students with a comfort package during 14-day mandatory quarantine In response to the upsurge of COVID-19 cases in the proximate college districts in Daejeon, KAIST announced the enforcement of stricter health and safety regulations. Korean health authorities expected another surge of COVID-19 cases this spring as Korea’s daily new COVID-19 cases have rebounded to the high 600s and over 700 in April, which is t2021-04-16
KAIST researchers have developed a novel nanofiber production technique called ‘centrifugal multispinning’ that will open the door for the safe and cost-effective mass production of high-performance polymer nanofibers. This new technique, which has shown up to a 300 times higher nanofiber production rate per hour than that of the conventional electrospinning method, has many potential applications including the development of face mask filters for coronavirus protection. Nanofibers2021-04-12
- The collective intelligence and technological innovation of KAIST was highlighted with case studies including the Post-COVID-19 New Deal R&D Initiative Project. - KAIST’s innovative academic achievements and R&D efforts for addressing the world’s greatest challenges such as the COVID-19 pandemic were featured in ACS Nano as part of its special virtual issue commemorating the 50th anniversary of KAIST. The issue consisted of 14 review articles contributed by KAIST facult2021-03-05
KAIST is proud to announce the graduation of 2,712 students, including 668 PhDs and 1,331 master’s degree recipients. The pandemic could not stop the university from recognizing each graduate's remarkable and original achievements. A pandemic-proof blended commencement ceremony was held on Friday, February 19, and livestreamed to the graduates and their loved ones. KAIST decided to take extra precautions to protect graduates and other attendees’ health and well-being. For the vi2021-02-19
KAIST announced that its spring 2021 classes will also be online as the pandemic continues into the new year. The spring semester will begin on March 1. Executive Vice President and Provost Kwang Hyung Lee said in a letter to the KAIST community on January 15 that nearly all classes in the 2021 spring semester will be held online. However, a very limited number of lab classes and other classes that require on-site practice and demonstrations will be offered either in-person or in a blended fo2021-02-04